20% decrease in average out-of-pocket expenses for Medicare beneficiaries by end of 2025?
Yes • 50%
No • 50%
Reports from the Centers for Medicare & Medicaid Services (CMS) or other official government health statistics
Medicare Implements $2,000 Annual Cap on Prescription Drug Costs Under Inflation Reduction Act
Dec 31, 2024, 09:50 PM
Starting January 1, Medicare will implement a new annual cap on out-of-pocket prescription drug costs at $2,000 for beneficiaries, a move anticipated to save millions of Americans money on their medications. This cap, part of the Inflation Reduction Act, will apply to drugs purchased at pharmacies or through mail order, offering significant relief to those who require multiple medications. The provision aims to limit the financial burden on Medicare enrollees, who previously faced no limit on out-of-pocket costs for medications covered by their Part D drug plans.
View original story
25% to 50% • 25%
More than 75% • 25%
Less than 25% • 25%
50% to 75% • 25%
No • 50%
Yes • 50%
$1,000 to $2,000 • 25%
$500 to $1,000 • 25%
Less than $500 • 25%
More than $2,000 • 25%
Wegovy • 25%
Xtandi • 25%
Ozempic • 25%
Trelegy Ellipta • 25%
$5 billion to $10 billion • 25%
Less than $5 billion • 25%
More than $15 billion • 25%
$10 billion to $15 billion • 25%
Approved as proposed • 25%
Modified and approved • 25%
Rejected • 25%
No decision by end of 2025 • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
No • 50%
Yes • 50%
Middle-income beneficiaries • 25%
Pharmaceutical companies • 25%
High-income beneficiaries • 25%
Low-income beneficiaries • 25%
Increased premiums or taxes • 25%
Insufficient cap amount • 25%
Implementation issues • 25%
Negative impact on drug innovation • 25%